Dogwood Therapeutics, Inc. (DWTX) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is bullish — 1 Buy.
Analysts estimate Earnings Per Share (EPS) of $-6.03 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-9.42 vs est $-6.03 (missed -56.2%). 2025: actual $-4.32 vs est $-6.62 (beat +34.7%). Analyst accuracy: 55%.
DWTX Analyst Ratings
Buy
Based on 1 analysts giving stock ratings to Dogwood Therapeutics, Inc. in the past 3 months
EPS Estimates — DWTX
55%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$9.42
vs Est –$6.03
▼ 36.0% off
2025
Actual –$4.32
vs Est –$6.62
▲ 53.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — DWTX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
